First systematic chiral syntheses of two pairs of enantiomers with 3,5-dihydroxyheptenoic acid chain, associated with a potent synthetic statin NK-104

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 20, 1999, Pages 2977-2982

  Suzuki, Mikio ^a   Yanagawa, Yoshinobu ^a   Iwasaki, Hiroshi ^a   Kanda, Hiroyasu ^a   Yanagihara, Kazufumi ^a   Matsumoto, Hiroo ^a   Ohara, Yoshio ^a   Yazaki, Yukari ^a   Sakoda, Ryozo ^a  

^a NISSAN CHEMICAL INDUSTRIES LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 [2 CYCLOPROPYL 4 (4 FLUOROPHENYL) 3 QUINOLYL] 3,5 DIHYDROXY 6 HEPTENOIC ACID DERIVATIVE; PITAVASTATIN; UNCLASSIFIED DRUG;

ARTICLE; DRUG SYNTHESIS; ENANTIOMER; ISOMER; STEREOCHEMISTRY;

HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; QUINOLINES; STEREOISOMERISM;

EID: 0033581607     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00519-3     Document Type: Article

References (34)

1. (a) Aoki, T.; Nishimura, H.; Nakagawa, S.; Kojima, J.; Suzuki, H.; Tamaki, T.; Wada, Y.; Yokoo, N.; Sata, F.; Kimata, H.; Kitahara, M.; Toyoda, K.; Sakashita, M.; Saito, Y. Arzneimittel-Forschung / Drug Research 1997, 47, 904.
2. (b) New Current 1995, 6, No. 6, 27.
3. (c) New Current 1996, 7, No. 15, 2.
4. (d) Drugs of the Future 1998, 23(8), 847.
5. (e) Tamaki, T.; Nakagawa, S.; Suzuki, H.; Wada, Y.; Shibuta, T.; Kakishita, T.; Kitahara, M.; Saito, Y. Abstract Book, P23, XI International Symposium on Drugs Affecting Lipid Metabolism, Florence, May 13-16, 1992: NK-104, a new potent HMG-Co.A reductase inhibitor (1); Evaluation as a hypolipaemic.
6. (f) Sakashita, M.; Toyoda, K.; Kitahara, M.; Wada, Y.; Saito, Y. Ibid., P22: NK-104, a new potent HMG-Co. A reductase inhibitor (2); The effect on cholesterol synthesis and proliferation of smooth muscle cells.
7. (g) Nakaya, N.; Kojima, J.; Kimata, H.; Kuwahata, R.; Narusima, H. Abstract Book, XII International Symposium on Drugs Affecting Lipid Metabolism, Houston, Nov. 7-10, 1995: NK-104; Efficacy and tolerance of a new synthetic HMG-Co.A reductase inhibitor in hypercholesterolemic volunteers.
8. (h) Kitahara, M.; Kanaki, T.; Tanaka, S.; Tamaki, T.; Saito, Y. Ibid.: Inhibition of HMG-CoA reductase by NK-104 suppresses intimal thickening via inhibiting smooth muscle cell growth and matrix formation in balloon injured rabbit artery.
9. Nakamura, C. E.; Abeles, R. H. Biochemistry 1985, 24, 1364. See the review of HMGR inhibitors;
10. Jahng, Y. Drug of the Future 1995, 20, 387.
11. (a) Takano, S.; Kamikubo, T.; Sugihara, T.; Suzuki, M.; Ogasawara, K. Tetrahedron Asymmetry 1993, 4(2), 201.
12. (b) Miyachi, N.; Suzuki, M; Ohara, Y.; Hiyama, T. J. of Synthetic Organic Chemistry, Japan 1995, 53, 186 and the references cited in.
13. (c) Hiyama, T.; Reddy, G.B.; Minami, T.; Hanamoto, T. Bull. Chem. Soc. Jpn. 1995, 68, 350.
14. (d) Hiyama, T.; Minami, T.; Takahashi, K. Ibid., 1995, 68, 364.
15. (e) Takahashi, K.; Minami, T.; Ohara, Y.; Hiyama, T. Ibid., 1995, 68, 2649.
16. (f) Hiyama, T. Pure & Appl. Chem. 1996, 68(3), 609.
17. (a) Stokker, G. E.; Hoffman, W. F.; Alberts, A. W.; Cragoe, E. J. Jr.; Deana, A. A.; Gilfillan, J. L.; Huff, J. W.; Novello, F. C.; Prugh, J. D.; Smith, R. L.; Willard, A K. J. Med. Chem. 1985, 28, 347.
18. (b) Hoffman, W. F.; Alberts, A. W.; Cragoe, Jr. E. J.; Deana, A. A.; Evans, B. E.; Gilfillan, J. L.; Gould, N. P.; Huff, J. W.; Novello, F. C.; Prugh, J. D.; Rittle, K. E.; Smith, R. L.; Stokker, G. E.; Willard, A. K. J.Med.Chem., 1986, 29, 159.
19. The syntheses and evaluations of the four stereoisomers of 3,5-dihydroxyheptanoic acid type inhibitor, compactin by Wadsworth-Emmons coupling followed by partially syn stereoselective reduction and HPLC separation were reported: (c) Heathcock, C.H.; Hadley, C. R.; Rosen, T.; Theisen, P. D.; Hecker, S. J. J.Med.Chem.1987, 30, 1858.
20. With respect to the several 3,5-dihydroxyheptenoic acid type synthetic inhibitors, their enantiomers were synthesized: (d) Stokker, G. E.; Alberts, A. W.; Anderson, P. S.; Cragoe, Jr. E. J.; Deana, A. A.; Gilfillan, J. L.; Hirshfield, J.; Holtz, W. J.; Hoffman, W. F.; Huff, J. W.; Lee, T. J.; Novello, F. C.; Prugh, J. D.; Rooney, C. S.; Smith, R. L.; Willard, A. K. J.Med.Chem., 1986, 29, 170.
21. (e) Parker, R. A; Clark, R. W.; Sit, S. Y.; Lanier, T. L.; Grosso, R. A.; Kim Wright, J. J. J. of Lipid Research, 1990, 31, 1271.
22. (f) Sit, S. Y.; Parker, R. A.; Motoc, I.; Han, W.; Balasubramanian, N.; Catt, J. D.; Brown, P. J.; Harte, W. E.; Thompson, M. D.; Wright, J. J. J. Med. Chem., 1990, 33, 2982.
23. (g) Roth, B. D.; Blankley, C. J.; Chucholowski, A. W.; Ferguson, E.; Hoefle, M. L.; Ortwine, D. F.; Newton, R. S.; Sekerke, C. S.; Sliskovic, D. R.; Stratton, C. D.; Wilson, M. W. J. Med. Chem., 1991, 34, 357.
24. (h) Kathawala, F. G.; Medicinal Research Reviews, 1991, 11, 121.
25. (a) Miyachi, N.; Yanagawa, Y.; Iwasaki, H.; Ohara, Y.; Hiyama, T. Tetrahedron Letters, 1993, 34, 8267.
26. (b) Fujikawa, Y.; Suzuki, M.; Iwasaki, H.; Sakashita, M.; Kitahara, M. E. P. Patent 304,063, 1989.
27. Chen, K-M.; Hardtman, G. E.; Prasad, K.; Repic, O.; Shapiro, M. J. Tetrahedron Letters, 1987, 28, 155.
28. 3CN : MeOH = 100 : 5 : 10, 30°C. (c) The diastereomeric purities of 6a and 6b; Nucleosil 50-5, 4.6 φ × 250 mm × 2, THF : n-hexane = 20 : 80, 35°C. (d) The enantiomeric purities of 7a and 7b; Chiralpack-AS, 4.6 φ × 250 mm, i-PrOH : n-hexane = 4 : 96, 35°C. (e) The enantiomeric purities of 2a and 2b; Chiralpack-AS, 4.6 φ × 250 mm, i-PrOH : n-hexane = 10 : 90, 35°C.
29. Ohara, Y.; Suzuki, M.; Yanagawa, Y.; Iwasaki, H.; Miyachi, N. E. P. Patent 520,406, 1993.
30. (a) Braun, M.; Devant, R. Tetrahedron Lett. 1984, 25, 5031.
31. D = +212° (c=1 in pyridine).
32. The syntheses of optical active ß -keto- δ -hydroxy esters were originally realized by Claisen condensation reaction with t-butyl acetoacetate. Lynch, J. E.; Volante, R. P.; Wattley, R. V.; Shinkai, I. Tetrahedron Letters, 1987, 28, 1385.
33. A practical process for optical resolution of the racemic ß -keto- δ -hydroxy esters ((±)-2) was achieved by Daicel Chemical Industries, Ltd. through the batch system with Chiralpak-AS, i-propanol : n-hexane = 5 : 95 vol/vol. Matsumoto, H.; Ohara, Y.; Kanda, H.; Ikeda, H. E. P. Patent 747,341, 1997.
34. Evans, D. A.; Chapman, K. T.; Carreira, E. M. J.Am.Chem.Soc. 1988, 110, 3560.